Evolus rises on upbeat prelim Q4 revenue

Evolus

17/01/2024 15:46

(Updates)
    ** Shares of cosmetic drug maker Evolus  EOLS.O  rise 16.2%
to a near one-and-half-year high of $12.12
    ** Company reports prelim Q4 revenue of $61 mln vs LSEG est
of $58.54 mln
    ** Says Q4 revenue driven primarily by higher volumes from
market share gains
    ** Company expects 2024 net revenue to be between $255 mln
and $265 mln, vs analysts' est of $257.5 mln
    ** Evolus' shares rose ~40% in 2023

 (Reporting by Sriparna Roy in Bengaluru)
 ((Sriparna.Roy@thomsonreuters.com))